Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Weighted Average): 2018-2025

Historic Shares Outstanding (Weighted Average) for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $69.3 million.

  • Bicycle Therapeutics' Shares Outstanding (Weighted Average) rose 0.45% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 0.45%. This contributed to the annual value of $69.0 million for FY2024, which is 62.76% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Shares Outstanding (Weighted Average) stood at $69.3 million, which was down 0.00% from $69.3 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Shares Outstanding (Weighted Average) peaked at $69.3 million during Q2 2025, and registered a low of $23.1 million during Q1 2021.
  • Over the past 3 years, Bicycle Therapeutics' median Shares Outstanding (Weighted Average) value was $69.0 million (recorded in 2024), while the average stood at $54.7 million.
  • Data for Bicycle Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 129.65% (in 2024) over the last 5 years.
  • Over the past 5 years, Bicycle Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $29.4 million in 2021, then grew by 0.99% to $29.7 million in 2022, then skyrocketed by 42.88% to $42.4 million in 2023, then spiked by 62.76% to $69.0 million in 2024, then climbed by 0.45% to $69.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $69.3 million in Q3 2025, compared to $69.3 million in Q2 2025 and $69.3 million in Q1 2025.